Oncothyreon (ONTY)

company web-site - http://www.oncothyreon.com
recent event / CC - http://ir.oncothyreon.com/events.cfm -

Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications.  Oncothyreon is headquartered in Bellevue, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY.   We are The Cancer Vaccine People(TM).

Stimuvax

ONTY's drug Stimuvax, in partnership with Merck KGaa, is now in large Phase 3 Pivotal Trial program for NSCLC:

Phase III NSCLC (Lung) "START" Trial - http://www.clinicaltrials.gov/ct2/show/NCT00409188

Phase III NSCLC "INSPIRE" Trial (Asia) - http://www.clinicaltrials.gov/ct2/show/NCT01015443

Phase II NSCLC w/Avastin Trial - http://www.clinicaltrials.gov/ct2/show/NCT00828009

Phase I/II NSCLC Trial in Japan -  http://www.clinicaltrials.gov/ct2/show/NCT00960115

Phase IV Long-Term Safety Trial - http://www.clinicaltrials.gov/ct2/show/NCT01423760

Phase II HDPC Trial - http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0247

 Pipe-Line - http://www.oncothyreon.com/pipeline/overview.html

Remaining Pipe-Line -

ONT-10 - http://www.oncothyreon.com/pipeline/vaccines/ONT-10/overview.html

PX-866 - http://www.oncothyreon.com/pipeline/small/PX-866/overview.html

          Start of Trial with Taxotere - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=526661

          Start of Trial with Erbitux - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953

PRESS RELEASES

Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Glioblastoma - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561867

Oncothyreon Presents Preclinical Data for ONT-10 and PX-866 at American Association for Cancer Research - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561521

Oncothyreon Announces Publication of Safety & Survival Data From Stimuvax Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788

Oncothyreon Initiates Phase 1/2 Trial of its PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953

Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=480296

Oncothyreon announces temporary suspension of Stimuvax clinical trials - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=453976

Oncothyreon announces STRIDE Phase 3 BC trial - June 22, 2009 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38926533

Oncothyreon announces clinical data at ASCO - May 30, 2009 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38259984

Oncothyreon announces development plans - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355043

Merck KGaA buys manufacturing rights for Stimuvax - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355037

ONTY/Merck KGaA amend agreements - Aug 8, 2007http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D....

MEDICAL PRESENTATIONS

ASCO 2007 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32165

"16 pts were evaluated for this interim safety analysis ..........As of September 2006, 10 pts were still on study treatment."

ASCO 2008 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34755

"The 2-year survival rate of 64% ....compares favorably with previously reported survival for chemoradiation in stage III NSCLC."

ASCO 2009 Stimuvax Abstract - http://www.abstract.asco.org/AbstView_65_31704.html

"a remarkable # of pts received prolonged treatment...16 pts received L-BLP25 for 2.0-7.7 years, 10 pts were treated for >5 years."

COMPLETE MEDICAL PAPERS

  Paper summarizing all Stimuvax trials to date - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39761211

  Publication of Data From Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788 

  A Peptide Vaccine Strategy in NSCLC - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39627241

 Phase IIb Trial in NSCLC Stage IIIB and IV - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39099793

"The greatest difference in survival was observed in stage IIIB LR patients (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069)"

 - Fig 3. Overall survival by study arm - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F3

 - Fig 4. Survival analysis for stage IIIB with MFE or stage IV patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F4

 - Fig 5. Survival analysis for stage IIIB locoregional patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F5

 Detailed Description of START Trial - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39062424

First Interim Look - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58060227